Lidocaine-prilocaine Cream as Analgesia for In-office Levator Muscle Trigger Point Injections

Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexFemale
Age18+
SponsorWomen and Infants Hospital of Rhode Island

About this trial

Levator muscle trigger point injections (TPI) are a commonly performed procedure in the office for treatment of pelvic pain related to pelvic floor muscles. The most common concern related to in-office TPI is pain. Currently, there is limited information about which medications could reduce pain during TPI. Pain control during in-office gynecologic procedures is a very important topic, and doctors are researching possible options for pain control during these procedures. Lidocaine-prilocaine cream is U.S Food and Drug Administration (FDA) approved for use on the genital area as pretreatment for procedures involving needles. The purpose of this study is to assess if vaginal lidocaine-prilocaine cream reduces pain with TPI compared to a placebo cream.

Eligibility criteria

Qualifiers

Patients 18 years or older

Patients who are undergoing in-office levator muscle trigger point injection for myofascial pelvic pain

Able to give informed consent for the study

Disqualifiers

Documented allergy to lidocaine or prilocaine

Use of lidocaine or prilocaine within last 72 hours

Trial design

Treatments tested in this trial

  • Lidocaine-Prilocaine Cream 2.5-2.5%
  • Permeation-enhancing vanishing cream

Treatment groups

36 Participants
are divided into 2 treatment groups

Locations

This trial has no locations